All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know ALL.
During the 64th American Society of Hematology (ASH) Annual Meeting and Exposition, the ALL Hub was pleased to speak to Nicholas Short, MD Anderson Cancer Center, Houston, US. We asked, Does adding inotuzumab ozogamicin to frontline therapy improve survival outcomes for adults with B-ALL?
Does adding inotuzumab ozogamicin to frontline therapy improve survival outcomes for adults with B-ALL?
Short begins by discussing the recent improvements in overall survival for patients with B-ALL following the introduction of inotuzumab ozogamicin, particularly in the relapsed/refractory setting. Short then outlines several combination treatments that include this anti-CD22 antibody-drug conjugate and their resulting long-term survival rates. The difference in response between older and younger adults is also discussed. Short concludes by looking to the future of combination and sequential therapies within standard treatment which could further improve outcomes and reduce the need of transplant in patients with ALL.
The effect of inotuzumab ozogamicin treatment exposure and cycles on R/R ALL outcomes
Inotuzumab ozogamicin (InO) is an anti‐CD22 monoclonal antibody conjugated to calicheamicin that has been licensed by the European Medicines Agency (EMA) and the...
The current treatment landscape of acute lymphoblastic leukemia
Acute lymphoblastic leukemia (ALL) is a rare hematological disorder with a bimodal incidence in childhood and in older adults. The advent of multiple chemotherapies has drastically...
Subscribe to get the best content related to ALL delivered to your inbox